Association of Systemic immune-inflammation index With Short-Term Mortality of Congestive Heart Failure: A Retrospective Cohort Study

1 Yiyang Tang¹, Yilu Feng¹, Qin Chen¹, Xiaofang Zeng¹, Zhenghui Liu², Hui Luo³, Lihuang

- 2 $\mathbf{Zha^{1*}}$ and $\mathbf{Zaixin} \mathbf{Yu^{1*}}$
- ³ ¹ Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan, People's
- 4 Republic of China
- ⁵ ² Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, People's
- 6 Republic of China
- ³ Department of Cardiovascular Medicine, the First Hospital of Changsha, Changsha, Hunan,
- 8 People's Republic of China

9 * Correspondence:

- 10 Zaixin Yu
- 11 yuzaixin@126.com
- 12 Lihuang Zha
- 13 <u>zhalihuang@csu.edu.cn</u>

Keywords: congestive heart failure₁, systemic immune-inflammation index₂, mortality₃, biomarker₄, MIMIC-III₅.

16 Abstract

17 **Purpose:** The present study aimed to clarify the potential predictive significance of Systemic

- 18 immune-inflammation index (SII) in assessing the poor prognosis of critically ill patients with 19 congestive heart failure (CHF).
- 20 Methods: Detailed clinical data were extracted from the Multiparameter Intelligent Monitoring in
- 21 Intensive Care III database after gaining access and building the local platform. The 30- and 90-day
- and hospital all-cause mortalities of the patient was the primary outcome, and the readmission rate
- and the occurrence of major cardiovascular adverse events (MACEs) were the secondary outcomes.
- 24 the Cox proportional hazard model and Logistic regression analysis were selected to reveal the
- 25 relationship between SII level and the research outcome. Further, the propensity score matching
- 26 (PSM) analysis was performed to improve the reliability of results by reducing the imbalance across
- 27 groups.
- 28 **Results:** There were a total of 4604 subjects who passed the screening process and entered the
- 29 subsequent analysis. Multivariate regression analysis showed that after adjusting for possible
- 30 confounders, including age, heart rate, and albumin, etc., the high level of SII was independently
- associated with 30- and 90-day and hospital mortality (tertile 3 versus tertile 1: HR, 95% CIs: 1.23,
- 32 1.04-1.45; 1.21, 1.06-1.39; 1.26, 1.05-1.50) and the incidence of MACEs (tertile 3 versus tertile 1:
- 33 OR, 95% CI: 1.39, 1.12-1.73) in critically ill patients with CHF, but no significant correlation was
- 34 found between SII and the readmission rate. Consistently, patients with high SII level still had a
- 35 significantly higher short-term mortality than patients with low SII in the PSM subset.

SII in heart failure

36 **Conclusion:** In critically ill patients with CHF, high level SII effectively predict high 30- and 90-day 37 and hospital mortalities, and the high risk of occurrence of MACEs.

38 1 Introduction

39 Congestive heart failure (CHF) is defined as a pathological condition in which the cardiac output is 40 insufficient to maintain the perfusion and metabolic needs of various tissues and organs, mainly 41 characterized by the congestion of pulmonary circulation, accompanied by the corresponding clinical 42 manifestations such as shortness of breath and decreased activity tolerance¹. CHF is the severe or 43 terminal stage of most primary cardiovascular diseases and has increasingly become a major public 44 problem threatening human health. In the United States and Europe, more than 1 million heart failure 45 patients are hospitalized each year, and as the population ages, this number is expected to increase by 46 more than 50% in the next 15 years². In addition, although some progress has been made in the 47 treatment in recent years, the prognosis of CHF patients is still poor, with 5-year mortality rate as 48 high as 40-50%³. Therefore, accurate assessment and stratification of prognosis are critical to the 49 clinical management of CHF, and the development of certain prognostic-related biomarkers is also 50 pressing, which can help clinicians to identify high-risk patients early and take more aggressive

51 treatment measures⁴.

52 Although the specific pathogenesis of heart failure remains unclear, abnormal immune activation and

53 chronic inflammation play an important role. The damage, repair and remodeling of myocardium are

54 important links in the occurrence and development of heart failure, of which immune/inflammatory

55 cells (neutrophils, lymphocytes, etc.) and the inflammatory factors (tumor necrosis factor,

⁵⁶ interleukin-6, etc.) released by them are involved⁵. Inflammatory factors can induce cardiomyocyte

57 hypertrophy, apoptosis and fibrosis, and ultimately lead to adverse cardiac remodeling and

58 progressive left ventricular dysfunction⁶. Inflammatory factors have been considered to be

biomarkers for poor prognosis of heart failure, and anti-inflammatory therapy is also expected to

60 become a new target for the treatment of heart failure⁷.

61 Systemic immune-inflammation index (SII) is a composite inflammatory indicator that combines

62 three significant immune cells, including neutrophil, lymphocyte, and platelet, and is considered to

63 be an excellent indicator of local immune response and systemic inflammation⁸. Neutrophils,

64 platelets and the cytokines they produce are mainly related to non-specific immune responses, while 65 lymphocytes are considered to be mainly related to specific immune pathways. Compared with the

65 lymphocytes are considered to be mainly related to specific immune pathways. Compared with the 66 absolute count of single immune cells, SII has a better representation in reflecting the inflammation

67 status of the body, with better stability. Until now, SII has been confirmed to is closely correlated

68 with the poor prognosis of a variety of cardiovascular diseases, including coronary artery disease⁹,

69 aortic stenosis¹⁰, infective endocarditis¹¹, etc., showing good application prospects, but no studies

70 have shown that SII is correlated with the prognosis of patients with CHF. In view of this, the present

study attempted to elucidate the independent association between SII and the occurrence of adverse

events such as short-term mortality in critically ill patients with CHF, so as to provide reference for

the prevention and treatment of heart failure.

74 2 Materials and Methods

75 2.1 Data Sources

76 All data used in the research and analysis of this study are derived from MIMIC-III (Medical

77 Information Mart for Intensive Care III) database, a free and open-access large-scale critical care

78 medicine database developed and run by the Massachusetts Institute of Technology for researchers

SII in heart failure

79 all over the world. Another advantage of this database, in addition to including the detailed clinical

- data such as demographic data, vital signs, laboratory tests, and various treatment information, is that 80
- 81 it provides accurate death information of all subjects, including deaths in the hospital or within 90
- 82 days after discharge, which makes it possible for the clinicians to carry out the prognostic related
- research. Besides, since this database has been approved by the local ethics committee as a whole and 83
- 84 the individual identifying information of the research subjects has been deleted, this study no longer
- 85 needs additional ethical approval.

86 2.2 **Population Selection and Exclusion**

- The subjects of this study are all from the MIMIC-III database¹², and patients who meet all the 87
- following requirements are included in the subsequent analysis: (1) Patients diagnosed with CHF 88
- based on the ICD-9 code (code 428.0); (2) Adult patients 18 years of age and older; (3) First 89
- 90 admission to ICU. Patients who met one of the following criteria were excluded from the study: (1)
- 91 The length of ICU stay was shorter than 24 hours; (2) Absence of SII results during hospitalization;
- 92 (3) Survival time was less than 0 (the time of death of some organ donors may be earlier than the
- 93 admission). The detailed process of inclusion and exclusion of research objects is shown in Figure 1.

94 2.3 **Study Outcomes**

95 The short-term mortality, including the 30- and 90-day and hospital all-cause mortalities of critically

- 96 ill patients with CHF, were selected as the primary study outcome, while the secondary study
- 97 outcome events were defined as the patients' readmission rate and the occurrence of major adverse
- cardiac events (MACEs), which is a composite outcome event, including all-cause death, 98
- 99 readmission for acute heart failure, the use of mechanical circulatory support and the implementation
- of heart transplantation¹³. 100

101 2.4 **Data Extraction and Integration**

- 102 Through the PostgreSQL software (version 9.6, https://www.postgresql.org/), we extracted detailed
- 103 clinical data of the research subjects from the MIMIC-III database, including demographic data (age,
- 104 gender, race, etc.), comorbidities (hypertension, diabetes mellitus, atrial fibrillation, etc.), vital signs
- 105 (heart rate, blood pressure, respiratory rate, etc.), severity of illness scores (SOFA and SAPSII
- 106 scores), laboratory tests (blood routine, electrolytes, etc.) and intervention measures (dialysis,
- mechanical ventilation, etc.). And the value of SII is equal to the product of the platelet count and the 107
- neutrophil count divided by the lymphocyte count¹⁴. 108
- 109 After separately extracting the required tables from the MIMIC-III database, the Stata software
- 110 (version 16, https://www.stata.com/) was used to process and merge these original table and generate
- a complete table that can be used for subsequent analysis. Use the "winsorize" function to identify 111
- 112 and process outliers, and fill in missing values through multiple compensation methods.

113 2.5 **Statistical Analyses**

- 114 The continuous variables were presented in the form of mean \pm standard deviation (SD) or median
- 115 (interquartile range). If continuous variables satisfy both normal distribution and homogeneity of
- 116 variance, one-way analysis of variance is used for analysis, while the Mann-Whitney U test was
- 117 conducted if the normal distribution or homogeneity of variance were not satisfied. Categorical
- 118 variables are expressed in the form of the number of cases (percentage), with the chi-square test (or
- 119 Fisher's exact method) for analysis.

SII in heart failure

- 120 We constructed a generalized additive model (GAM) to determine the non-linear relationship
- between SII and 30- and 90-day all-cause mortality in critically ill patients with CHF. In addition, we
- also visually show the relationship between SII and patients' survival through the Kaplan-Meier (K-
- 123 M) curve, and use the Log-rank test for hypothesis testing.

124 In order to relieve the interference of possible confounding factors on the results, we completed 125 univariate and multivariate regression analysis to further clarify the relationship between SII and 126 outcome variables. In the crude model, no variables were adjusted. In model I, the age, gender, and 127 race variables were adjusted, while model II further adjusted other 13 variables on the basis of these variables of model II, including heart rate, blood urea nitrogen (BUN), albumin, troponin T (cTnT), 128 129 N-terminal probrain natriuretic peptide (NT-proBNP), urine output of first day, cardiac index, the 130 type of first ICU admission, the use of mechanical ventilation and vasopressor, pneumonia, and liver diseases. The selection of confounding factors follows the following principles¹⁵: (1) A certain factor 131 132 has an influence of more than 10% on the research variable; (2) Some factors may have a significant 133 impact on the outcome variable based on past experience. Besides, we use the variance inflation 134 factor (VIF) to test the multicollinearity between variables with 5 as the threshold, and the variables

- 135 with a high degree of collinearity, serum chloride, were deleted to avoid over-fitting of the model.
- 136 The Cox regression analysis was used to determine the relationship between SII and short-term
- 137 mortality in critically ill patients with CHF, while Logistic regression analysis was used to analyze
- 138 the association between SII and readmission rates or MACEs.
- 139 To further enhance the credibility of our analysis, we performed the subgroup analysis and
- 140 propensity score matching (PSM) analysis. First, By the subgroup analysis, determine whether the
- 141 correlation between the SII and the high 30-day all-cause mortality in critically ill patients with CHF
- 142 is consistent across various subgroups stratified mainly by comorbidities, and reflect the stability of
- 143 SII as a prognostic marker. The optimal cut-off value of SII for the short-term mortality was
- determined by the X-tile (version 3.6.1, Yale University School of Medicine) software, and then the
- entire study population was divided into two groups, namely the high SII group and the low SII group. In this study, all variables with uneven distribution between the two groups of patients were
- 146 group. In this study, all variables with uneven distribution between the two groups of patients were 147 included in the PSM model as covariates, and the corresponding propensity score was calculated by
- included in the PSM model as covariates, and the corresponding propensity score was calculated by
 Logistic regression. Then the two groups of individuals with similar propensity scores were matched
- by 1:1 using nearest neighbor matching method with a caliper width of 0.05, and the histogram of the
- propensity score distribution was draw, which was carried out through the Stata software. Then, K-M
- 151 curves were depicted and Cox regression analysis was conducted in the matching cohort after PSM,
- which further validated SII as an independent risk factor for poor prognosis in the critically ill
- 153 patients with CHF.
- 154 The statistical analysis above was conducted by EmpowerStats software (version 2.20,
- 155 http://www.empowerstats.com/cn/, X&Y solutions, Inc, Boston, MA) and R software (version 3.4.3).
- 156 p <0.05 (two-sided) was considered statistically significant.

157 **3 Results**

158 **3.1** Clinical Characteristics of Study Subjects

159 The study subjects were screened according to the process shown in Figure 1, and 4604 subjects were

- 160 finally included. The demographic data, vital signs, comorbidities, treatment, scores and laboratory
- examinations and other relevant information are shown in Table 1 in detail. In general, the study
- subjects included were a little old, with a median age of 74.91 years old, mainly male patients, 162
- reaching 2436, accounting for 52.89%. And the majority of the subjects were whites, accounting for

164 72.71%, blacks only 7.21%, and other races including Asians accounted for 20.08%. The duration of

follow-up was 90 days, of which 3226 survived and 1380 died due to various reasons before the end 165

of the study. SII (213.97 vs 163.11, p<0.001) was significantly higher in the non-survivor cohort. 166 167 Compared with the survivor group, older patients were identified more frequently in the non-survivor

- group, with more unstable vital signs, higher incidence of comorbidities such as VHD, atrial 168
- 169 fibrillation, and renal failure, as well as higher SOFA and SAPSII scores.

170 3.2 SII Distinguishing a Poor Short-term Prognosis

GAM analysis was used to identify the non-linear correlation between SII and the short-term all-171

172 cause mortality of patients, which showed that there was a U-shaped curve relationship between SII

173 and 30-day (Figure 2A) and 90-day (Figure 2B) all-cause mortality in critically ill patients with CHF,

174 indicating that higher or lower SII may be associated with increased mortality. The K-M survival

curve (Figure 3) also showed that compared with the low SII group, patients with high SII level had a 175

- 176 lower overall survival rate and shorter survival time, with a statistically significant p value.
- 177 In order to verify the independent relationship between SII and the poor short-term mortality of CHF

178 patients, we performed the univariate and multivariate Cox regression analysis (Table 2), with SII

179 stratified by tertiles. In crude model, the third tertile of SII increased significantly the risk of 30- (HR,

180 95% CI: 1.73, 1.48-2.03) and 90-day (HR, 95% CI: 1.65, 1.45-1.88) and hospital (HR, 95% CI: 1.61,

1.36-1.91) all-cause mortalities compared with the first tertile. In multivariate model I, after adjusting 181

182 for age, sex, and ethnicity, the third tertile of SII group also suffered from the higher risk of 30- (HR, 183 95% CI: 1.63, 1.40-1.91) and 90-day (HR, 95% CI: 1.57, 1.38-1.79) and hospital (HR, 95% CI: 1.45,

184 1.22-1.72) all-cause mortalities. In model II, in addition to adjusting for the variables in model I and

185 other possible confounders such as pneumonia, the use of dialysis, and BUN level, high levels of SII

186 were still strongly associated with poor 30- (HR, 95% CI: 1.23, 1.04-1.45) and 90-day (HR, 95% CI:

187 1.21, 1.06-1.39) and hospital (HR, 95% CI: 1.26, 1.05-1.50) all-cause mortalities.

188 3.3 Association between SII and readmission and MACEs

189 For MACEs, a similar trend was observed. In model II (Table 3), patients with an SII \geq 2730.11 were

190 still at higher incidence of MACEs (OR, 95% CI: 1.39, 1.12-1.73). However, in the multivariate

191 regression analysis, there was no obvious independent correlation between SII and readmission rate

in the critically ill patients with CHF (tertile 3 versus tertile 1: OR, 95% CI: 0.97, 0.81-1.15). 192

193 3.4 **Subgroup analyses**

194 The subgroup analysis was conducted to reveal the correlation between SII and 30-day mortality

195 across comorbidities and different parameters, and the results were shown in Table 4. First, the

196 results of the study showed that in all subgroups, the increase in SII level was closely related to the

197 increase in the 30-day all-cause mortality of critically ill patients with CHF. Besides, most of the

198 stratification factors have not been found to have a significant impact on the relationship between the

199 SII and 30-day all-cause mortality in critically (interaction p value>0.05), except for hyperlipemia

200 (p=0.006) and AMI (p=0.016). The above results indicated that SII has good robustness as a marker

201 for poor prognosis of CHF.

202 **Prognostic value of SII after PSM** 3.5

203 Determine the optimal cut-off value of SII for 90-day all-cause mortality of critically ill patients with 204 CHF through X-tile software, which is 5533.4. Subjects were divided into two groups according to

- 205 the cut-off value, and their clinical characteristics were summarized in Table 5, most of which were
- 206 unevenly distributed across the two groups. In order to effectively balance these confounding factors
- and improve the credibility of our results, we conducted a PSM analysis with 1:1 matching. After
- PSM, 602 pairs of research objects were generated and the difference of almost all variables were
- balanced between the two groups, with a good matching performance (Figure 4). At the same time,after PSM, compared with the low SII level group, subjects in the high SII level group still
- underwent higher 30- (24.9% vs 33.2%, p=0.002) and 90-day (35.0% vs 42.0%, p=0.013) and
- hospital (22.4% vs 27.7%, p=0.033) all-cause mortality, with shorter survival time (Table 5 and
- Figure 5). Besides, after adjusting for these covariable in the model II, the increased SII was also
- associated with increased risk of short-term all-cause mortality in critically ill patients with CHF after
- 214 associated with increased fisk of short-term an-cause montality in children in patient 215 DSM and the results were shown in Figure 6 in the form of a forest mon
- 215 PSM and the results were shown in Figure 6 in the form of a forest map.

216 **4 Discussion**

217 CHF is widespread all over the world, with gradually increasing incidence with age, and has become

- one of the diseases with the highest rates of hospitalizations and deaths in the world, bringing about
- enormous medical expenditure and social burden, especially in developing countries¹⁶. In addition to
- exploring promising treatments, the development of novel prognostic markers for risk stratification
- of patients is also of great value for improving the prognosis of patients. As we all know, as a
- commonly used indicator of heart failure, NT-proBNP can make a good performance in prognostic
 evaluation. However, the clinical applications of NT-proBNP for risk assessment has some
- 225 evaluation. However, the chinical applications of N1-proBNP for fisk assessment has some
- drawbacks and problems. First, compared to the real value, the detection of NT-proBNP tend to be underestimated because of the short half-life. Moreover, the test of NT-proBNP may be affected by
- various factors such as age, gender, and kits¹⁷. Therefore, the search for more possible biomarkers
- 227 has gradually attracted the attention of researchers and clinicians.
- In the present study, we extracted the clinical data of 4604 critically ill patients who diagnosed with
- 229 CHF between 2003 and 2010 in MIMIC-III database, and analyzed the relationship between SII and
- short-term prognosis by univariate and multivariate regression analyses for the first time. And the
- results have verified that SII could be an independent biomarker for poor short-term prognosis of
- 232 CHF. There was a nonlinear relationship between SII and 30- and 90-day mortalities. And the higher
- SII level, the higher risk of 30- and 90-day and hospital mortalities, as well as the higher incidence of
- MACEs. The correlation remained significant after adjusting for possible confounders, stratifying
- according to comorbidities, and PSM matching, respectively.

Inflammation, a widely accepted hallmark of heart failure, has been proven to play an indispensable 236 role in the pathogenesis of heart failure¹⁸. The increase and activation of inflammation-related 237 238 cytokines not only present a reflection of the activation of inflammation in vivo, but have also been 239 identified as being associated with poor prognosis in heart failure. Tumor necrosis factor α (TNF- α) 240 was the first cytokine found to be significantly elevated in the serum of patients with heart failure, 241 which could directly induce myocardial apoptosis and necrosis, bringing about ventricular adverse 242 remodeling¹⁹. The elevated levels of TNF- α often indicated impaired cardiac systolic function and poor long-term survival²⁰. In addition, interleukin 6 (IL-6), another classic cytokine mainly derived 243 244 from monocytes, could be significantly increased in patients with left ventricular systolic dysfunction 245 without clinical symptoms, and may be a sensitive indicator for the early diagnosis of heart failure²¹. IL-6 was also positively correlated with the severity of heart failure, the concentration of which was 246 negatively correlated with left ventricular ejection fraction and overall survival²². Although these 247 248 inflammatory molecules had good performance in the prognostic evaluation of patients, the

expensive detection cost limited their clinical application. As a novel biomarker, SII can

SII in heart failure

250 systematically and comprehensively reflect the status of inflammation in vivo. Blood routine is a

- 251 routine examination for almost all hospitalized patients. It is simple, fast, and inexpensive. Compared
- with NT-proBNP, cytokines and other prognostic indicators, SII can effectively screen high-risk
- 253 patients, guide the formulation of individualized treatment plans and improve the prognosis of
- 254 patients without additional cost, with a broad application prospect, especially in underdeveloped
- areas.

256 The mechanisms of the relationship between SII and adverse prognosis of CHF remains unclear, and possible explanations are as follows. Recently, it has been revealed that circulating immune cells and 257 their subtypes had a vital indicative effect on the prognosis of cardiovascular diseases²³. SII was a 258 259 prognostic indicator that integrates three circulating immune cells, including neutrophils, 260 lymphocytes, and platelets, the increase of which indicates either a relative increase in platelets and 261 neutrophils counts or a relative decrease in lymphocytes. Neutrophils are the main component of 262 white blood cells, accounting for 60-70% of the total, and play an important role in the non-specific 263 immune system. In the inflammatory response, neutrophils react rapidly, with strong chemotaxis and phagocytosis, and participate in the progression of various cardiovascular diseases, including heart 264 failure²⁴. In addition, neutrophils could contribute to oxidative stress and endothelial dysfunction by 265 266 releasing a large amount of myeloperoxidase, NADPH oxidase, and so on²⁵. According to a community-based study²⁶, absolute neutrophils can effectively predict the increased incidence of 267 268 acute decompensated heart failure after acute myocardial infarction, and it was also an independent risk factor for death²⁷. Lymphocytes mainly consist of two subtype including T and B cells, which 269 270 were often associated with the specific immunity. Several previous studies have reported that 271 lymphocyte counts in patients with heart failure were lower than in the normal population and 272 lymphopenia served as an independent predictor of poor survival of patients with chronic and advanced heart failure^{28,29}. Lymphopenia was considered to be an important feature of systemic 273 274 inflammation, which may be caused by the following mechanisms. First, the circulating lymphocytes 275 were attracted into the cardiac tissue, leading to its redistribution. Then, lymphopenia was related to 276 the activation of renin-angiotensin-aldosterone hormone and the adrenergic nervous system, which could exert pro-apoptotic effects on lymphocytes²⁹. Platelets were differentiated from the 277 278 mononuclear-phagocyte system and were the key mediator linking the two pathological processes of inflammation and thrombosis³⁰. On the one hand, platelets were the main effector molecules for 279 280 hemostasis after cardiovascular injury. On the other hand, the activation of platelets plays a major 281 role in pathogenic thrombosis and participates in the pathogenesis of many groups of cardiovascular diseases, including coronary heart disease³¹. Moreover, Platelets interacted with leukocytes and their 282 283 subtypes (neutrophil, lymphocytes, etc.) and endothelial cells and activated them, inducing monocyte 284 adhesion and transport, releasing inflammatory factors such as TNF- α and IL-1, which together promoted local inflammation and fibrosis in heart failure³¹. The study by Kandis³² et al. demonstrated 285 286 that mean platelet volume (MPV), indicating the activation of platelets, increased significantly in 287 decompensated heart failure patients. In addition, MPV at admission was independently associated 288 with the hospital and 6-month mortalities.

But at the same time, there were certain limitations in this study. First, the present study was

290 conducted at a single center and did not validate the prognostic value of SII in a validation cohort.

291 Second, the clinical data were collected retrospectively from databases and it was difficult to ensure

that variables were evenly distributed across groups, although multiple regression models were

293 conducted to adjust for confounders and PSM analysis was used to minimize inter-group differences 294 in baseline characteristics. Third, some significant variables may be omissive due to the lack of data.

- in baseline characteristics. Third, some significant variables may be omissive due to the lack of data.
 Last, this study was unable to determine the underlying mechanism of the association between high
- 295 Last, this study was unable to determine the underlying mechanism of the association between in 206 SII and poor prognosis of CHE patients, and further experiments are pecessary.

SII and poor prognosis of CHF patients, and further experiments are necessary.

SII in heart failure

297 **5** Conclusion

In summary, the high level of SII is closely related to the poor short-term prognosis in critically ill patients with CHF, including 30- and 90-day and hospital all-cause mortality, as well as the

300 occurrence of MACEs, and is expected to be a simple and effective prognostic evaluation indicator.

301 6 Conflict of Interest

302 All authors declare that there is no conflict of interest.

303 7 Author Contributions

- 304 Zaixin Yu and Lihuang Zha are the senior author who conceived and designed the study. Yiyang
- 305 Tang and Qin Chen collected and analyzed the clinical data. Yiyang Tang drafted the manuscript.
- 306 Yilu Feng and Xiaofang Zeng participated in the implementation of statistical methods in this study
- 307 and put forward constructive suggestions. Zhenghui Liu and Hui Luo reviewed the study and
- 308 participated in the interpretation of the results. All authors gave final approval of the version to be
- 309 published, and agree to be accountable for all aspects of the work.

310 **8 Funding**

- 311 Our study was supported by the National Natural Science Foundation of China (81873416), the Key
- 312 Research and Development Program of Hunan Province (2020SK2065) and Natural Science
- 313 Foundation Project of Hunan Province (2020JJ4634).

314 9 Data availability

- 315 Publicly available datasets were analyzed in this study. This data can be extracted from Monitoring in
- 316 Intensive Care Database III version 1.4 (MIMIC-III v.1.4) after passing on the required courses and
- 317 obtaining the authorization.

318 **Reference styles**

- Sun D, Zhang F, Ma T, Zhang Y, Liang Z. Atorvastatin alleviates left ventricular remodeling in isoproterenol-induced chronic heart failure in rats by regulating the RhoA/Rho kinase signaling pathway. *Pharmacol Rep.* 2020;72(4):903-911.
- Povsic TJ. Emerging Therapies for Congestive Heart Failure. *Clin Pharmacol Ther*.
 2018;103(1):77-87.
- Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. *JAMA*.
 2011;306(15):1669-1678.
- 327 4. Xu M, Zhang L, Song S, et al. Hydrogen sulfide: Recent progress and perspectives for the
 328 treatment of dermatological diseases. *J Adv Res.* 2021;27:11-17.
- Li H, Chen C, Wang DW. Inflammatory Cytokines, Immune Cells, and Organ Interactions in
 Heart Failure. *Front Physiol.* 2021;12:695047.
- Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha
 and myocardial remodeling in progression of heart failure: a current perspective. *Cardiovasc Res.* 2002;53(4):822-830.

334 7. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 335 2015;116(7):1254-1268. 336 8. Wang BL, Tian L, Gao XH, et al. Dynamic change of the systemic immune inflammation 337 index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. 338 *Clin Chem Lab Med.* 2016;54(12):1963-1969. 339 9. Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted 340 clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 341 2020;50(5):e13230. 342 10. Tosu AR, Kalyoncuoglu M, Biter HI, et al. Prognostic Value of Systemic Immune-343 Inflammation Index for Major Adverse Cardiac Events and Mortality in Severe Aortic 344 Stenosis Patients after TAVI. Medicina (Kaunas). 2021;57(6). 345 11. Agus HZ, Kahraman S, Arslan C, et al. Systemic immune-inflammation index predicts mortality in infective endocarditis. J Saudi Heart Assoc. 2020;32(1):58-64. 346 347 12. Johnson AE, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. 348 Sci Data. 2016;3:160035. 349 13. Li W, Huang A, Zhu H, et al. Gut microbiota-derived trimethylamine N-oxide is associated 350 with poor prognosis in patients with heart failure. Med J Aust. 2020;213(8):374-379. 351 14. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of 352 patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 353 2014;20(23):6212-6222. 354 15. Jaddoe VW, de Jonge LL, Hofman A, Franco OH, Steegers EA, Gaillard R. First trimester 355 fetal growth restriction and cardiovascular risk factors in school age children: population based cohort study. BMJ. 2014;348:g14. 356 357 16. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 358 2017;3(1):7-11. 359 17. Cho JH, Cho HJ, Lee HY, et al. Neutrophil-Lymphocyte Ratio in Patients with Acute Heart 360 Failure Predicts In-Hospital and Long-Term Mortality. J Clin Med. 2020;9(2). 361 18. Dick SA, Epelman S. Chronic Heart Failure and Inflammation: What Do We Really Know? 362 Circ Res. 2016;119(1):159-176. 363 19. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. 364 Heart. 2004;90(4):464-470. 365 20. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in 366 patients with chronic heart failure. Circulation. 2000;102(25):3060-3067. 367 21. Plenz G, Song ZF, Tjan TD, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail. 2001;3(4):415-421. 368 369 22. Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical significance of 370 interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 371 2019;21(8):965-973. 372 23. Strassheim D, Dempsey EC, Gerasimovskaya E, Stenmark K, Karoor V. Role of 373 Inflammatory Cell Subtypes in Heart Failure. J Immunol Res. 2019;2019:2164017.

- Bonaventura A, Montecucco F, Dallegri F, et al. Novel findings in neutrophil biology and
 their impact on cardiovascular disease. *Cardiovasc Res.* 2019;115(8):1266-1285.
- Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and
 heart failure. *Science*. 2013;339(6116):161-166.
- Arruda-Olson AM, Reeder GS, Bell MR, Weston SA, Roger VL. Neutrophilia predicts death
 and heart failure after myocardial infarction: a community-based study. *Circ Cardiovasc Qual Outcomes.* 2009;2(6):656-662.
- 381 27. Uthamalingam S, Patvardhan EA, Subramanian S, et al. Utility of the neutrophil to
 382 lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. *Am*383 *J Cardiol.* 2011;107(3):433-438.
- Vaduganathan M, Ambrosy AP, Greene SJ, et al. Predictive value of low relative lymphocyte
 count in patients hospitalized for heart failure with reduced ejection fraction: insights from
 the EVEREST trial. *Circ Heart Fail*. 2012;5(6):750-758.
- 29. Charach G, Grosskopf I, Roth A, et al. Usefulness of total lymphocyte count as predictor of outcome in patients with chronic heart failure. *Am J Cardiol.* 2011;107(9):1353-1356.
- 389 30. Ye GL, Chen Q, Chen X, et al. The prognostic role of platelet-to-lymphocyte ratio in patients
 390 with acute heart failure: A cohort study. *Sci Rep.* 2019;9(1):10639.
- 391 31. Glezeva N, Gilmer JF, Watson CJ, Ledwidge M. A Central Role for Monocyte-Platelet
 392 Interactions in Heart Failure. *J Cardiovasc Pharmacol Ther.* 2016;21(3):245-261.
- 393 32. Kandis H, Ozhan H, Ordu S, et al. The prognostic value of mean platelet volume in decompensated heart failure. *Emerg Med J.* 2011;28(7):575-578.
- 395
- 396
- 397
- 398
- 399
- 400
- 401
- -01
- 402
- 403
- 404
- 405
- 406
- 407

SII in heart failure

Parameter	All(n=4606)	Survivors (n=3226)	Non-survivors (n=1380)	p value
Demographics				
Age, years	74.91 (64.06-83.07)	72.70 (61.97-81.65)	78.94 (69.40-84.82)	< 0.001
Male, n (%)	2436 (52.89%)	1690 (52.39%)	746 (54.06%)	0.298
Ethnicity, n (%)				< 0.001
White	3349 (72.71%)	2361 (73.19%)	988 (71.59%)	
Black	332 (7.21%)	254 (7.87%)	78 (5.65%)	
Others	925 (20.08%)	611 (18.94%)	314 (22.75%)	
Vital signs				
HR, beats/minute	85.02 (74.53-96.54)	84.33 (74.33-95.77)	86.67 (75.24-98.65)	< 0.001
RR, times/minute	19.42 (16.87-22.38)	19.17 (16.76-21.91)	20.03 (17.24-23.45)	< 0.001
SBP, mmHg	113.64 (104.46-125.96)	114.89 (105.50-126.98)	111.04 (101.60-123.48)	< 0.001
DBP, mmHg	56.93 (50.87-63.71)	57.85 (51.64-64.34)	55.10 (49.46-61.64)	< 0.001
Temperature, °C	36.76 (36.37-37.21)	36.80 (36.42-37.22)	36.65 (36.26-37.13)	< 0.001
SpO2, %	97.23 (95.74-98.46)	97.25 (95.81-98.49)	97.19 (95.52-98.40)	0.018
Weight, kg	77.75 (64.70-93.60)	79.80 (65.60-96.00)	73.80 (62.00-88.00)	< 0.001
Therapies, n (%)				
ACEI	1266 (27.49%)	1012 (31.37%)	254 (18.41%)	< 0.001
ARB	183 (3.97%)	151 (4.68%)	32 (2.32%)	< 0.001
β-blocker	2827 (61.38%)	2074 (64.29%)	753 (54.57%)	< 0.001
Digoxin	475 (10.31%)	303 (9.39%)	172 (12.46%)	0.002
Furosemide	3190 (69.26%)	2275 (70.52%)	915 (66.30%)	0.004
Statins	1451 (31.50%)	1121 (34.75%)	330 (23.91%)	< 0.001
Dialysis	478 (10.38%)	278 (8.62%)	200 (14.49%)	< 0.001
Vasopressor	1234 (26.79%)	727 (22.54%)	507 (36.74%)	< 0.001
Ventilation	1879 (40.79%)	1133 (35.12%)	746 (54.06%)	< 0.001
Assisted circulation	282 (6.12%)	186 (5.77%)	96 (6.96%)	0.123

Table 1. The baseline clinical characteristics of critically ill patients with CHF. 408

409 **Table 1.** Continued.

Parameter	All(n=4606)	Survivors (n=3226)	Non-survivors (n=1380)	p value
Laboratory events				
Hemoglobin, g/dl	10.90 (9.70-12.30)	11.10 (9.80-12.50)	10.70 (9.40-11.90)	< 0.001
Creatinine, mg/dl	1.20 (0.90-1.80)	1.20 (0.90-1.70)	1.30 (0.90-2.10)	< 0.001
BUN, mg/dl	27.00 (18.00-43.00)	25.00 (17.00-40.00)	33.00 (21.00-51.00)	< 0.001
Glucose, mg/dl	135.33 (115.00-166.12)	134.23 (115.47-164.03)	137.71 (114.36-170.52)	0.111
Sodium, mmol/L	139.00 (136.00-141.00)	139.00 (136.00-141.00)	138.00 (135.00-141.00)	0.023
Potassium, mmol/L	4.20 (3.80-4.60)	4.10 (3.70-4.60)	4.20 (3.80-4.70)	0.002
Chloride, mmol/L	103.00 (99.00-107.00)	103.00 (99.25-107.00)	103.00 (99.00-107.00)	0.035
Bicarbonate, mmol/L	24.00 (21.00-28.00)	25.00 (22.00-28.00)	24.00 (20.00-27.00)	< 0.001
PT, second	14.30 (13.20-16.80)	14.20 (13.10-16.50)	14.80 (13.40-17.90)	< 0.001
APTT, second	31.80 (27.30-40.40)	31.30 (27.10-40.20)	32.70 (27.87-41.10)	0.001
Lactate, mmol/L	1.82 (1.30-2.90)	1.80 (1.20-2.83)	2.00 (1.30-3.00)	< 0.001
Albumin, g/dL	3.00 (2.56-3.40)	3.00 (2.60-3.42)	2.89 (2.45-3.24)	< 0.001
Bilirubin, mg/dL	1.40 (0.60-3.05)	1.40 (0.60-3.00)	1.41 (0.60-3.10)	0.339
ALT, IU/L	60.00 (22.00-298.33)	69.00 (23.92-327.15)	45.00 (19.00-207.75)	< 0.001
NT-proBNP, ng/ml	10.98 (4.67-18.83)	10.70 (4.26-18.34)	11.91 (5.67-19.96)	< 0.001
cTnT, ng/mL	1.34 (0.10-2.87)	1.46 (0.11-2.94)	1.12 (0.09-2.58)	< 0.001
CI, L/min/m ²	2.76 (2.13-3.47)	2.75 (2.13-3.48)	2.78 (2.14-3.45)	0.626
Urine output, L	1.54 (0.89-2.44)	1.73 (1.02-2.65)	1.14 (0.67-1.87)	< 0.001
SII $\times 10$	174.76 (92.24-344.55)	163.11 (88.62-309.02)	213.97 (105.80-430.34)	< 0.001
Hospitalization type				< 0.001
Emergency, n (%)	4062 (88.19%)	2804 (86.92%)	1258 (91.16%)	
Elective, n (%)	367 (7.97%)	300 (9.30%)	67 (4.86%)	
First ICU admission				< 0.001
CCU, n (%)	1236 (26.83%)	898 (27.84%)	338 (24.49%)	
MICU, n (%)	2005 (43.53%)	1308 (40.55%)	697 (50.51%)	

SII in heart failure

Table 1. Continued.

Parameter	All(n=4606)	Survivors (n=3226)	Non-survivors (n=1380)	p value
Comorbidities, n (%)				
Hypertension	937 (20.34%)	655 (20.30%)	282 (20.43%)	0.919
Hyperlipemia	1260 (27.36%)	975 (30.22%)	285 (20.65%)	< 0.001
Diabetes mellitus	1657 (35.97%)	1218 (37.76%)	439 (31.81%)	< 0.001
Atrial fibrillation	2077 (45.09%)	1361 (42.19%)	716 (51.88%)	< 0.001
AMI	346 (7.51%)	241 (7.47%)	105 (7.61%)	0.871
VHD	463 (10.05%)	289 (8.96%)	174 (12.61%)	< 0.001
Peripheral vascular	577 (12.53%)	397 (12.31%)	180 (13.04%)	0.489
Pulmonary circulation	292 (6.34%)	183 (5.67%)	109 (7.90%)	0.005
Pneumonia	1350 (29.31%)	858 (26.60%)	492 (35.65%)	< 0.001
COPD	245 (5.32%)	156 (4.84%)	89 (6.45%)	0.025
Liver diseases	232 (5.04%)	138 (4.28%)	94 (6.81%)	< 0.001
Renal failure	1120 (24.32%)	757 (23.47%)	363 (26.30%)	0.040
Stroke	250 (5.43%)	148 (4.59%)	102 (7.39%)	< 0.001
Hypothyroidism	555 (12.05%)	392 (12.15%)	163 (11.81%)	0.746
Malignancy	253 (5.49%)	128 (3.97%)	125 (9.06%)	< 0.001
Depression	359 (7.79%)	276 (8.56%)	83 (6.01%)	0.003
Scores				
SOFA	5.00 (3.00-7.00)	4.00 (3.00-6.00)	6.00 (4.00-8.00)	< 0.001
SAPSII	40.00 (32.00-49.00)	38.00 (30.00-46.00)	47.00 (39.00-56.00)	< 0.001
Length of ICU stay, h	94.00 (50.00-187.00)	88.00 (48.00-166.75)	122.00 (62.00-240.25)	< 0.001

SII in heart failure

Table 2. The univariate and multivariate Cox regression analysis exploring the association of SII 416

tertile with short-term mortality of critically ill patients with CHF. 417

	Crude		Model I		Model II	
	HR (95%CIs)	P value	HR (95%CIs)	P value	HR (95%CIs)	P value
30-day all-cause mortality						
SII	1.00 (1.00, 1.00)	< 0.001	1.00 (1.00, 1.00)	< 0.0001	1.00 (1.00, 1.00)	< 0.0001
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.17 (0.99, 1.38)	0.067	1.14 (0.97, 1.35)	0.112	1.05 (0.89, 1.25)	0.524
≥2730.11	1.73 (1.48, 2.03)	< 0.001	1.63 (1.40, 1.91)	< 0.001	1.23 (1.04, 1.45)	0.011
P for trend	< 0.001		<0.001		<0.001	
90-day all-cause mortality						
SII	1.00 (1.00, 1.00)	< 0.001	1.00 (1.00, 1.00)	< 0.0001	1.00 (1.00, 1.00)	0.001
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.12 (0.97, 1.28)	0.114	1.10 (0.96, 1.27)	0.168	1.02 (0.88, 1.17)	0.820
≥2730.11	1.65 (1.45, 1.88)	< 0.001	1.57 (1.38, 1.79)	< 0.001	1.21 (1.06, 1.39)	0.005
P for trend	< 0.001		< 0.001		< 0.001	
Hospital all-cause mortality						
SII	1.00 (1.00, 1.00)	< 0.001	1.00 (1.00, 1.00)	< 0.0001	1.00 (1.00, 1.00)	0.002
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.27 (1.06, 1.52)	0.008	1.21 (1.01, 1.45)	0.035	1.17 (0.97, 1.40)	0.096
≥2730.11	1.61 (1.36, 1.91)	< 0.001	1.45 (1.22, 1.72)	< 0.001	1.26 (1.05, 1.50)	0.011
P for trend	< 0.001		<0.001		< 0.001	

418

419

SII in heart failure

Table 3. The univariate and multivariate Logistic regression analysis exploring the association of SII 421 tertile with readmission and MACEs of critically ill patients with CHF. 422

		Crude		Model I		Model II	
		OR (95%CIs)	P value	OR (95%CIs)	P value	OR (95%CIs)	P value
	Readmission						
	SII (tertile)						
	<1144.28	1 (ref)		1 (ref)		1 (ref)	
	≥1144.28, <2730.11	0.91 (0.77, 1.07)	0.253	0.94 (0.80, 1.11)	0.472	0.94 (0.80, 1.11)	0.484
	≥2730.11	0.88 (0.75, 1.04)	0.129	0.93 (0.78, 1.10)	0.392	0.97 (0.81, 1.15)	0.703
	P for trend	< 0.001		< 0.001		< 0.001	
	MACEs						
	SII (tertile)						
	<1144.28	1 (ref)		1 (ref)		1 (ref)	
	≥1144.28, <2730.11	1.17 (1.02, 1.35)	0.030	1.17 (1.02, 1.35)	0.028	0.92 (0.74, 1.13)	0.417
	≥2730.11	2.01 (1.73, 2.32)	< 0.001	2.02 (1.74, 2.35)	< 0.001	1.39 (1.12, 1.73)	0.003
	P for trend	< 0.001		< 0.001		< 0.001	
3							
Ļ							
5							
5							
7							
3							
)							
)							
-							
2							
3							
,							

SII in heart failure

	Ν		SII		P for
	· · · · ·	<1144.28	≥1144.28, <2730.11	≥2730.11	interaction
Hypertension					0.178
No	3669	1.0 (ref)	1.09 (0.90, 1.31)	1.70 (1.44, 2.02)	
Yes	937	1.0 (ref)	1.57 (1.07, 2.31)	1.88 (1.28, 2.76)	
Diabetes					0.384
No	2949	1.0 (ref)	1.16 (0.95, 1.42)	1.62 (1.34, 1.95)	
Yes	1657	1.0 (ref)	1.22 (0.90, 1.65)	2.01 (1.52, 2.67)	
Hyperlipemia					0.006
No	3346	1.0 (ref)	1.13 (0.94, 1.36)	1.51 (1.27, 1.80)	
Yes	1260	1.0 (ref)	1.40 (0.96, 2.05)	2.77 (1.94, 3.96)	
AMI					0.016
No	4260	1.0 (ref)	1.09 (0.92, 1.30)	1.71 (1.46, 2.01)	
Yes	346	1.0 (ref)	2.63 (1.30, 5.30)	2.31 (1.14, 4.69)	
VHD					0.602
No	4143	1.0 (ref)	1.15 (0.96, 1.38)	1.76 (1.49, 2.07)	
Yes	463	1.0 (ref)	1.23 (0.76, 2.00)	1.50 (0.94, 2.41)	
PCD					0.931
No	4314	1.0 (ref)	1.17 (0.98, 1.39)	1.72 (1.46, 2.02)	
Yes	292	1.0 (ref)	1.15 (0.61, 2.19)	1.86 (1.05, 3.32)	
Atrial fibrillation					0.437
No	2529	1.0 (ref)	1.04 (0.82, 1.31)	1.59 (1.28, 1.98)	
Yes	2077	1.0 (ref)	1.29 (1.02, 1.64)	1.84 (1.47, 2.31)	
Pneumonia					0.061
No	3256	1.0 (ref)	1.18 (0.96, 1.44)	1.89 (1.56, 2.29)	
Yes	1350	1.0 (ref)	1.09 (0.82, 1.45)	1.33 (1.03, 1.74)	
COPD					0.962
No	4361	1.0 (ref)	1.16 (0.98, 1.38)	1.72 (1.47, 2.02)	
Yes	245	1.0 (ref)	1.32 (0.54, 3.20)	1.86 (0.83, 4.17)	
Liver diseases					0.065
No	4374	1.0 (ref)	1.26 (1.06, 1.50)	1.85 (1.57, 2.18)	
Yes	232	1.0 (ref)	0.62 (0.34, 1.13)	1.24 (0.70, 2.21)	

Table 4. Subgroup analysis of the relationship between SII and 30-day all-cause mortality. 435

SII in heart failure

Table 4. Continued.

	Ν		SII		P for
		<1144.28	≥1144.28, <2730.11	≥2730.11	interaction
Renal failure					0.396
No	3486	1.0 (ref)	1.10 (0.91, 1.33)	1.72 (1.44, 2.05)	
Yes	1120	1.0 (ref)	1.39 (1.00, 1.94)	1.79 (1.30, 2.48)	
Hypothyroidism					0.628
No	4051	1.0 (ref)	1.13 (0.95, 1.35)	1.71 (1.45, 2.01)	
Yes	555	1.0 (ref)	1.46 (0.90, 2.38)	1.96 (1.23, 3.12)	
Stroke					0.618
No	4356	1.0 (ref)	1.14 (0.96, 1.36)	1.69 (1.44, 1.99)	
Yes	250	1.0 (ref)	1.45 (0.79, 2.65)	2.24 (1.26, 3.97)	
Depression					0.216
No	4247	1.0 (ref)	1.17 (0.98, 1.39)	1.79 (1.52, 2.10)	
Yes	359	1.0 (ref)	1.11 (0.55, 2.25)	1.02 (0.51, 2.03)	
Malignancy					0.879
No	4353	1.0 (ref)	1.18 (0.99, 1.40)	1.72 (1.46, 2.02)	
Yes	253	1.0 (ref)	1.02 (0.57, 1.83)	1.57 (0.94, 2.63)	
SOFA					0.172
<5	2149	1.0 (ref)	1.24 (0.91, 1.70)	2.21 (1.66, 2.96)	
≥5	2457	1.0 (ref)	1.20 (0.99, 1.46)	1.58 (1.31, 1.90)	
SAPSII					0.255
<40	2181	1.0 (ref)	1.22 (0.87, 1.71)	1.99 (1.43, 2.75)	
≥40	2425	1.0 (ref)	1.13 (0.93, 1.37)	1.42 (1.19, 1.69)	

SII in heart failure

Table 5. The clinical characteristics in critically ill patients with CHF before and after PSM. 444

Parameter	B	Before PSM			After PSM	
	<5533.4	≥5533.4	P value	<5533.4	≥5533.4	P value
N	3995	611		602	602	602
Demographics						
Age, years	74.4 (63.4-82.9)	76.9 (68.2-83.7)	< 0.001	77.7 (66.1-84.2)	76.9 (68.1-83.7)	0.984
Male, n (%)	2154 (53.9%)	282 (46.2%)	< 0.001	279 (46.3%)	279 (46.3%)	1.000
Ethnicity, n (%)		0.001	0.001			0.526
White	2879 (72.1%)	470 (76.9%)		463 (76.9%)	461 (76.6%)	
Black	309 (7.7%)	23 (3.8%)		30 (5.0%)	23 (3.8%)	
Others	807 (20.2%)	118 (19.3%)		109 (18.1%)	118 (19.6%)	
Vital signs						
HR, beats/minute	84.5 (74.1-96.0)	88.2 (77.0-99.6)	< 0.001	87.5 (77.3-98.8)	87.9 (76.8-99.2)	0.840
RR, times/minute	19.3 (16.8-22.3)	20.3 (17.6-23.2)	< 0.001	20.2 (17.3-23.5)	20.2 (17.6-23.1)	0.876
SBP, mmHg	113.8 (104.6-126.0)	113.8 (104.6-126.0)	0.145	113.9 (103.4-125.6)	112.1 (103.5-125.7)	0.964
DBP, mmHg	57.1 (51.1-63.9)	55.7 (50.2-62.5)	0.009	55.3 (49.1-61.9)	55.6 (50.2-62.5)	0.219
Temperature, °C	36.8 (36.4-37.2)	36.7 (36.3-37.1)	0.010	36.8 (36.4-37.2)	36.7 (36.3-37.1)	0.254
SpO2, %	97.3 (95.8-98.5)	97.0 (95.5-98.4)	0.157	97.3 (95.6-98.5)	97.0 (95.5-98.4)	0.474
Weight, kg	78.4 (65.0-94.3)	74.4 (61.0-90.0)	< 0.001	73.0 (61.0-88.5)	74.4 (61.0-90.0)	0.560
Therapies, n (%)						
ACEI	1117 (28.0%)	149 (24.4%)	0.065	153 (25.4%)	147 (24.4%)	0.689
ARB	158 (4.0%)	25 (4.1%)	0.872	26 (4.3%)	25 (4.2%)	0.886
β-blocker	2454 (61.4%)	373 (61.0%)	0.858	373 (62.0%)	367 (61.0%)	0.722
Digoxin	411 (10.3%)	64 (10.5%)	0.888	85 (14.1%)	63 (10.5%)	0.053
Furosemide	2766 (69.2%)	424 (69.4%)	0.937	412 (68.4%)	416 (69.1%)	0.804
Statins	1274 (31.9%)	177 (29.0%)	0.148	158 (26.2%)	174 (28.9%)	0.302
Dialysis	426 (10.7%)	52 (8.5%)	0.104	86 (14.3%)	51 (8.5%)	0.001
Vasopressor	1042 (26.1%)	192 (31.4%)	0.008	171 (28.4%)	187 (31.1%)	0.313
Ventilation	1561 (39.1%)	318 (52.0%)	< 0.001	306 (50.8%)	310 (51.5%)	0.818
Assisted circulation	259 (6.5%)	23 (3.8%)	0.009	21 (3.5%)	23 (3.8%)	0.759
Scores						
SOFA	5.0 (3.0-7.0)	5.0 (3.0-7.0)	0.556	5.0 (3.0-7.0)	5.0 (3.0-7.0)	0.405
SAPSII	40.0 (32.0-49.0)	45.0 (36.0-53.5)	< 0.001	44.0 (35.0-53.0)	45.0 (36.0-53.0)	0.440

SII in heart failure

Table 5. Continued. 445

Parameter	B	efore PSM			After PSM	
	<5533.4	≥5533.4	P value	<5533.4	≥5533.4	P value
N	3995	611		602	602	
Laboratory events						
Hemoglobin, g/dl	11.0 (9.7-12.4)	10.7 (9.5-12.1)	0.008	10.7 (9.5-11.9)	10.7 (9.5-12.1)	0.290
Creatinine, mg/dl	1.2 (0.9-1.8)	1.2 (0.9-2.1)	0.250	1.3 (0.9-2.0)	1.2 (0.9-2.1)	0.160
BUN, mg/dl	26.0 (18.0-42.0)	30.0 (19.0-49.0)	< 0.001	31.0 (20.0-49.0)	30.0 (19.0-48.0)	0.613
Glucose, mg/dl	134.0 (114.4-163.6)	145.5 (119.7-176.8)	< 0.001	141.2 (117.1-180.3)	145.5 (119.6-176.2)	0.610
Sodium, mmol/L	139.0 (136.0-141.0)	138.0 (135.0-141.0)	< 0.001	138.0 (135.0-141.0)	138.0 (135.0-141.0)	0.487
Potassium, mmol/L	4.2 (3.8-4.6)	4.2 (3.7-4.7)	0.575	4.2 (3.8-4.7)	4.2 (3.7-4.7)	0.634
Chloride, mmol/L	103.0 (100.0-107.0)	102.0 (98.0-107.0)	< 0.001	103.0 (99.0-106.0)	102.0 (98.0-107.0)	0.377
Bicarbonate, mmol/L	25.0 (21.0-28.0)	24.0 (20.0-27.0)	< 0.001	24.0 (20.0-27.0)	24.0 (20.0-27.0)	0.878
PT, second	14.3 (13.2-16.8)	14.4 (13.2-17.1)	0.245	14.4 (13.2-17.3)	14.4 (13.2-17.2)	0.846
APTT, second	31.8 (27.3-41.1)	31.6 (27.3-38.6)	0.329	31.3 (27.3-40.2)	31.7 (27.3-38.7)	0.920
Lactate, mmol/L	1.9 (1.3-2.9)	1.8 (1.3-2.8)	0.654	1.8 (1.3-3.0)	1.8 (1.3-2.8)	0.654
Albumin, g/dL	3.0 (2.6-3.4)	2.9 (2.5-3.3)	< 0.001	2.8 (2.4-3.3)	2.9 (2.5-3.3)	0.255
Bilirubin, mg/dL	1.5 (0.6-3.1)	0.9 (0.4-2.5)	< 0.001	1.1 (0.5-2.4)	0.9 (0.4-2.6)	0.282
ALT, IU/L	62.0 (22.0-309.0)	50.0 (21.0-242.7)	0.034	51.0 (21.0-225.8)	50.0 (21.0-248.5)	0.637
NT-proBNP, ng/ml	10.9 (4.6-18.6)	12.1 (5.1-19.8)	0.019			
cTnT, ng/mL	1.4 (0.1-2.9)	1.1 (0.1-2.5)	0.016	1.1 (0.1-2.8)	1.1 (0.1-2.5)	0.768
CI, L/min/m ²	2.8 (2.1-3.5)	2.8 (2.2-3.5)	0.309	2.8 (2.1-3.4)	2.8 (2.2-3.5)	0.938
Urine output, L	1.6 (0.9-2.5)	1.4 (0.8-2.1)	< 0.001	1.4 (0.7-2.2)	1.4 (0.8-2.1)	0.522
Hospitalization type			0.002			0.238
Emergency, n (%)	3498 (87.6%)	564 (92.3%)		538 (89.4%)	555 (92.2%)	
Elective, n (%)	338 (8.5%)	29 (4.7%)		39 (6.5%)	29 (4.8%)	
First ICU admission			< 0.001			0.004
CCU, n (%)	1098 (27.5%)	138 (22.6%)		143 (23.8%)	138 (22.9%)	
Length of ICU stay, h	93.0 (50.0-184.0)	109.0 (54.0-204.0)	0.003	118.5 (59.0-228.8)	109.0 (53.0-201.8)	0.128
Comorbidities, n (%)						
Hypertension	830 (20.8%)	107 (17.5%)	0.062	126 (20.9%)	106 (17.6%)	0.144
Hyperlipemia	1120 (28.0%)	140 (22.9%)	0.008	133 (22.1%)	138 (22.9%)	0.730
Diabetes mellitus	1449 (36.3%)	208 (34.0%)	0.285	205 (34.1%)	205 (34.1%)	1.000


SII in heart failure

Table 5. Continued.

Parameter		Before PSM			After PSM	
	<5533.4	≥5533.4	P value	<5533.4	≥5533.4	P value
N	3995	611		602	602	
Comorbidities, n (%)						
Atrial fibrillation	1783 (44.6%)	294 (48.1%)	0.107	281 (46.7%)	290 (48.2%)	0.603
AMI	301 (7.5%)	45 (7.4%)	0.882	39 (6.5%)	44 (7.3%)	0.570
VHD	402 (10.1%)	61 (10.0%)	0.952	88 (14.6%)	61 (10.1%)	0.018
Peripheral vascular	511 (12.8%)	66 (10.8%)	0.167	88 (14.6%)	64 (10.6%)	0.037
Pulmonary circulation	239 (6.0%)	53 (8.7%)	0.011	45 (7.5%)	52 (8.6%)	0.459
Pneumonia	1108 (27.7%)	242 (39.6%)	< 0.001	235 (39.0%)	237 (39.4%)	0.906
COPD	188 (4.7%)	57 (9.3%)	< 0.001	48 (8.0%)	53 (8.8%)	0.603
Liver diseases	214 (5.4%)	18 (2.9%)	0.011	20 (3.3%)	18 (3.0%)	0.742
Renal failure	982 (24.6%)	138 (22.6%)	0.284	162 (26.9%)	136 (22.6%)	0.083
Stroke	227 (5.7%)	23 (3.8%)	0.051	38 (6.3%)	23 (3.8%)	0.052
Hypothyroidism	461 (11.5%)	94 (15.4%)	0.007	97 (16.1%)	92 (15.3%)	0.692
Malignancy	209 (5.2%)	44 (7.2%)	0.047	31 (5.1%)	43 (7.1%)	0.150
Depression	303 (7.6%)	56 (9.2%)	0.175	50 (8.3%)	56 (9.3%)	0.542
30-day mortality	769 (19.2%)	204 (33.4%)	< 0.001	150 (24.9%)	200 (33.2%)	0.002
90-day mortality	1120 (28.0%)	260 (42.6%)	< 0.001	211 (35.0%)	253 (42.0%)	0.013
Hospital-day mortality	659 (16.5%)	172 (28.2%)	< 0.001	135 (22.4%)	167 (27.7%)	0.033

SII in heart failure

457 **Figure 1**. Workflow for screening study subjects. ICU, intensive care unit.



458

Figure 2. The non-linear curve fitting of the association between SII and 30- (A) and 90- (B) day all cause mortalities in critically ill patients with CHF after adjusting for age, gender, race, and other

461 potential variables. SII, systemic immune-inflammation index. CHF, congestive heart failure.






Figure 3. Kaplan-Meier survival curves showing the 30- (A) and 90- (B) day all-cause mortalities
stratified by SII tertile in critically ill patients with CHF. SII, systemic immune-inflammation index.
CHF, congestive heart failure.





466

- **Figure 4.** The bar chart presenting the range of propensity scores and the corresponding number of
- 468 matches in high (red) and low (blue) SII groups. SII, systemic immune-inflammation index.



- 470 **Figure 5.** Kaplan-Meier survival curves showing the 30- (A) and 90- (B) day all-cause mortalities
- 471 stratified by cut-off value of SII in critically ill patients with CHF before PSM. C and D presented the
- 472 correlation between SII and 30- and 90-day mortalities after PSM, separately. SII, systemic immune-
- 473 inflammation index. CHF, congestive heart failure. PSM, propensity score matching.







475 Figure 6. The forest plot showing the univariate (A) and multivariate (B) Cox regression for effects

476 of SII on short-term mortality in the critically ill patients with CHF before and after PSM. SII,

477 systemic immune-inflammation index. CHF, congestive heart failure. PSM, propensity score478 matching.

SII in heart failure

А	Univariate analysis	p value	HR(95%CI)	
	Before PSM			
	30-day mortality	<0.0001	1.8841(1.6145, 2.1986)	├───
	90-day mortality	<0.0001	1.7045(1.4893, 1.9508)	⊢
	Hospital mortality	<0.0001	1.7299(1.4624, 2.0463)	⊢ I
	After PSM			
	30-day mortality	0.0014	1.4108(1.1416, 1.7435)	⊢ I
	90-day mortality	0.0075	1.2829(1.0686, 1.5402)	⊢
	Hospital mortality	0.0019	1.4352(1.1423, 1.8033)	⊢ i
				1.0 1.41 2.0
В	Multivariate analysis	p value	HR(95%CI)	
В	Multivariate analysis Before PSM	p value	HR(95%CI)	
В		p value <0.0001	HR(95%CI) 1.3930(1.1887, 1.6323)	⊢
В	Before PSM	·		الــــــــــــــــــــــــــــــــــــ
В	Before PSM 30-day mortality	<0.0001	1.3930(1.1887, 1.6323)	
В	Before PSM 30-day mortality 90-day mortality	<0.0001 0.0003	1.3930(1.1887, 1.6323) 1.2923(1.1254, 1.4840)	
В	Before PSM 30-day mortality 90-day mortality Hospital mortality	<0.0001 0.0003	1.3930(1.1887, 1.6323) 1.2923(1.1254, 1.4840)	
В	Before PSM 30-day mortality 90-day mortality Hospital mortality After PSM	<0.0001 0.0003 0.0004	1.3930(1.1887, 1.6323) 1.2923(1.1254, 1.4840) 1.3652(1.1486, 1.6226)	
В	Before PSM 30-day mortality 90-day mortality Hospital mortality After PSM 30-day mortality	<0.0001 0.0003 0.0004 0.0021	1.3930(1.1887, 1.6323) 1.2923(1.1254, 1.4840) 1.3652(1.1486, 1.6226) 1.4018(1.1306, 1.7380)	